Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
DOI:
https://doi.org/10.33448/rsd-v10i13.21052Keywords:
Venous thromboembolism; Pulmonary embolism; COVID-19; Clinical management.Abstract
Objective: to identify how the clinical management of patients infected with COVID-19 who present pulmonary thromboembolism and/or venous thromboembolism occurs. Method: This is an integrative review, carried out by searching for articles in the VHL, LILACS, MEDLINE, CINAHL AND SCOPUS databases, with a temporal delimitation from November 2019 to March 2021. Results: 24 articles were included. Diagnosis occurs through D-dimer and fibrinogen. For drug therapy, low molecular weight heparin (LMWH) is administered, 30 mg/12h in 12h for prophylactic anticoagulation, staggered doses of LMWH with enoxaparin, 0.5 mg/kg twice a day for anticoagulation therapy and rivoxaban 10mg/day for post-discharge anticoagulation. Conclusion: Clinical management of TEP and VTE occurs through increased D-dimer or fibrinogen, with TEP confirmed by pulmonary angiography. For anticoagulation, LMWH is mostly used.
References
Aryal, M. R., Gosain, R., Donato, A., Pathak, R., Bhatt, V. R., KateL, A. & Kouides, P. (2020). Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment. Current Cardiology Report, 22(52), 01-05.
Atallah, B., Sadik, G. B., Salem, N., Nekidy, W. S. E., Almahmeed, W., Park, W. M. … Mallat, J. (2021). The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Anaesthesia, 76, 327–335.
Bikdeli, M. S. D., Madavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E, … Lip, G. Y. H. (2020). COVID-19 e Trombotic ouDoença tromboembólica: Implicaçõespara prevenção, terapia antitrombótica,e Follow-Up. Journal of the American college of cardiology, 75(23), 2950-2973.
Billet, H. H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L.R. & Lo, Y. (2020). Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis and Haemostasis, 120(12), 1691-1699.
BRASIL- Biblioteca Virtual em Saúde (2021). Gerenciamento Clínico. Pesquisa | Portal Regional da BVS (bvsalud.org).
Bozzani, A., Arici, V., Tavazzi, G., Franciscone, M. M., Danesino, V., Rota, M. ... Ragni, F. (2020). Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy. Surgery, 98, 987-992.
Canoglu, K. & Saylan, B. (2020). Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. ANN SAUDI MED, 462-468.
Ciceri, F., Beretta, L., Scandroglio, A.M., Colombo, S., Landoni, G., Ruggeri, A., Peccatori, J., D’Angelo, A., Cobelli, F., Rovere-Querini, P., Tresoldi, M, Dagna, L. & Zangrillo, A. (2020). Microvascular COVID-19 síndrome tromboinflamatória obstrutiva dos vasos pulmonares (MicroCLOTS): uma hipótese de trabalho da síndrome da angústia respiratória aguda atípica. Crit Care Resusc., 22(02), 95-77.
Creel-Bulos, C., Lui, M., Auld, S. C., Gaddh, M., Kemptom, C. L., Sharipfour, M. … Rangaraju, S. (2020). Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease 2019. Medicine, 99(46), 01-08.
Cui, S., CheN, S., Li, X., liu, S. & Wang, F. (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost, 18(6): 1421-24.
Dobesh, P. P. & Trujillo, T. C. (2020). Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacoterapy, 40(11),01-53.
Eljilany, I. & Elzouki, A. (2020). D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vascular Health and Risk Management, 16, 455–462.
Fauvel, C., Weizman, O., Trimaille, A., Mika, D., Pommier, T., Pace, N. … Pezel, T. (2020). Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. European Heart Journal, 41(32), 3058-3068.
Fu, Z., Zhuang, X., He, Y., Huang, H & GUO, W. (2020). The diagnostic value of D-dimer with simplified Geneva score (SGS) pre-test in the diagnosis of pulmonary embolism (PE). Journal of Cardiothoracic Surgery, 15(176), 01-07.
Galvão, T. F., Pansani, T. S. A., Harrad, D. (2015). Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiol. Serv. Saúde, 24(02), 335-342.
Garcia-Olivé, I., Sintes, H., Radua, J., Capa, J.Á. & Rosell, A. (2020). D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respiratory Medicine, 169(106023), 01-03.
García-Ortega, A., Oscullo, G., Calvillo, P., MARTÍ-BONMATI, L., MENÉNDEZ, R. & MARTÍNEZ-GARCIA, M.A. (2020). Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection. Journal of infection, 82(02), 261-69.
Gomes, L. M., Marchiori, E. & Rodrigues, R. S. (2006). Trombose venosa profunda e suspeita de tromboembolismo pulmonar: avaliação simultânea por meio de angiotomografia pulmonar e venotomografia combinadas. Radiol Bras, 39(1), 19-26.
Haque, S., Jawed, A., Akhter, N., Dar, S. A., Khan, R. K., MandaL, M. Y. … YahiD, M. (2020). Acetylsalicylic acid (Aspirin): a potent medicine for preventing COVID-19 deaths caused by thrombosis and pulmonary embolism. Eur Rev Med Pharmacol Sci, 24(18),9244-9245.
Klok, F. A., Mos. I. C. M., Nijekeuter. M., Righini, M., Perrier, A. & GaL, L.G. (2008). Simplification of the Revised Geneva Score for Assessing Clinical Probability of Pulmonary Embolism. Arch intern med, 168(19), 2131-36.
Li, M., Gitarts, S., Nyabera, A., Kondaveeti, R., Hammudeh, Y. & Gonzalez, C. (2020). Continuous Infusion Low-Dose Unfractionated Heparin for the Management of Hypercoagulability Associated With COVID-19. Journal of Pharmacy Practice, 20(10), 01-07.
Liao, S., Shao, S., Chen, Y., Chen, Y. & PEndurado M. (2020) Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis. Critical Care, 464(24), 01-05.
Lippi, G., Plebani, M. & Henry, B. M. (2020). A trombocitopenia está associada a infecções graves por coronavírus 2019 (COVID-19): uma meta-análise. Clin Chim Acta, 506, 145-148.
Rossi, F. (2020). Tromboembolismo venoso em pacientes COVID-19. Jornal Vascular Brasileiro, 19, 01-05.
Lodigiani, C., Lapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T. ... Barco, S. (2020). Thrombosis Research,191,9–14.
Long, H., Nie, L., Xiang, X., Li, H., Zhang, X., Fu, X. … Wu, Q. (2020). D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. BioMed Research International, 01-10.
Manolis, A. S., Manolis, T. A. & Manolis, A. A. (2021). COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management. Journal of Cardiovascular Pharmacology and Therapeutics, 26(1), 12-24.
Marietta, M., Coluccio, V. & Luppi, M. (2020). COVID-19, coagulopatia e tromboembolismo venoso: mais perguntas do que respostas. Estagiário Emerg Med, 12(8), 01-13.
Marinho, F. P., Loyola, I. S., Monteiro, I. O. F., Castro, T. M., Carvalho, M. G. S. ... Santos, G. B. (2021). Inter-relação entre COVID-19 e diabetes mellitus: uma revisão sistemática. Research, Society and Development, 10(2), 01-14.
Mendes, K. D. S., Silveira, R. C. C. P. & Galvão, C. M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto Enfermagem, 17(4),758-64.
Melnyk, B. M. & Fineout-Overholt, E. (2005). Making the case for evidence-based practice.In: Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare. A guide to best practice. Philadelphia: Lippincot Williams & Wilkins, 3-24.
Mestre-Gómez, B., Lorente-Ramos, R. M., Rogado, J., Franco-Moreno, A., Obispo, B., Salazar-Chiriboga, D. ... Rivas, N. M. (2020). Incidence of pulmonary embolism in non critically ill COVID 19 patients. Predicting factors for a challenging diagnosis. Journal of Thrombosis and Thrombolysis, 51(01), 40-46.
Middeldorp, S., Coppens, M., Haaps, T. F. V., Foppen, M., Vlaar, A. P., Muller, M. C. A., Bouman, C. C. S., Beenen, F. F. M., Kootte, R. S., Heijmans, J., Smits, L. P., Bonta, P. & Es, N. V. (2020). Incidência de tromboembolismo venoso em pacientes hospitalizados com COVID-19. J Thromb Haemost., 18 (08),1995-2002.
Minno, A. D., Ambrosino, P., Calcaterra, I., Minno, M. N. D. D. (2020). COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Seminars in Thrombosis & Hemostasis, 46(7), 763-771.
Nadkarni, G. N., Lala, A., Bagiella, E., Chang, H. L., Moreno, P. R. & Pujadas, E. (2020). Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. Journal of the American college of Cardiology, 76 (16),1815-1826.
Nopp, S., Florian, K., Jilma, B., PabingeR, I. & A. Y, C. (2020). Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost, 4(07), 1178–1191.
Ooi, M. Y. X., Rajai, A., Patel, R., Gerova, N., Godhamgaokar, V. & Liong, S. Y. (2020). Pulmonary thromboembolic disease in COVID-19 patients on CT pulmonary angiography – Prevalence, pattern of disease and relationship to D-dimer. Europen jornal of radiology,132(109336), 01-07.
Parks, A. L., Auerbach, A. D., Schinipper, J. L., Anstey, J. E., sterken, D. G., Hecht, T. E. H. & Fang, M. C (2020). COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic. Trombosis Research, 196, 355-358.
Pavoni, V., Gianesello, L., Pazzi, M., Stera, C. & Meconi, T. (2020). Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. Trombosis Research, 196,313-317.
Poulakou, G., Dimakakos, E., Kollias, A., Kyriakoulis, K. G., Rapti, V., Trontzas, I. … Syrigos, K. N. (2021). Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study. In vivo, 35, 653-661.
Rashidi, F., Barco, S., Kamangar, F., Movalled, K., Ghorbani, O., Ansarin, K. ... Ansarin, K. (2021). Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. Trombosis research, 198,135-38.
Rentsch, C. T., Beckman, J. A., Tomlinson, L., Gellad, W. F., Alcorn, C., Kidway-Khan, F. … Freiberg, M. J. (2021). Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ, 372(31),01-13.
Robert-Ebadi, H., Mostaguir, K., Hovens, M., Kare, M., Verschuren, F., Girard, P., Huisman, M. V. … Gal, G. L. (2017). Acessing clinical probability of pulmonar embolism: prospective validation of the simplified Geneva score. T Tromb Haemost, 15(09), 1764-1769.
Rosovsky, R. P., Grodzin, C., Channick, R., Davis, G. A., Giri, J. S., Horowitz, J. … Rosenfield, K. (2020). Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic. Pulmonary and Cardiovascular: Special Features, 28(6),2590-2601.
Stessel, B., Vanvuchelen, C., Bruckers, L., Herbots, L., RamaekerS, D. & Dubois, J. (2020). Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study Trombosis research, 194, 209-215.
Smith, K., Krajeswki, K. C. & Krajeswiki, M. P. (2020). Practical Considerations in Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19. Am j health-syst pharm, 20(20), 01-07.
Spyropoulos, A. & Weitz, J. I. (2020). Hospitalized COVID-19 patients and venous tromboembolism. Circulation, 142(2),129-132.
Taccone, F. S., Gevenois, P. A., Peluso, L., Pletchette, Z., Lheureux, O., Bresseur, A. ... Vicent, J. (2020). Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients. Crit Care Med, 48(11), 1087-1090.
Tang, N., Bai, H., Chen, X., Gong, J., Li, D. & Sun, Z. (2020). Anticoagulant Treatment is associated with decreased mortality in severe coronavírus disease 2019 patients with coagulopathy. J trob Haemost, 18,1094-1099.
Trigonis, R. A., Holt, D. B., Yuan, R., Siddiqui, A. A., Craft, M. K., Khan, B. A. … Rahman, O. (2020). Incidence of Venous Thromboembolism in Critically Ill Coronavirus Disease 2019 Patients Receiving Prophylactic Anticoagulation. Critical Care medicine, 98(07), 805-808.
Valle, C., Bonafinni, P. A., Corso, M. D., Vacca, G., Gianatti, A. & Sironi, S. (2020). Association between pulmonary embolism and COVID-19 severe pneumonia: Experience from two centers in the core of the infection Italian peak. European Journal of radiology,137(109613),01-08.
Vernuccio, F., Lombardo, F. P., Cannella, R., Panzuto, F., giambeluca, D., Arzanauskaite, M. ... Cabassa, P. Thromboembolic complications of COVID-19: the combined effect of a pro-coagulant pattern and an endothelial thrombo-inflammatory syndrome. Clinical radiology 2020; 75(11):804-10.
Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Huang, B., Chen, Y. & Zhang, Y. (2020). COVID-19: immunopathogenesis and Immunotherapeutics. Sig Transduct Target Ther, 128(5), 01-08.
Zhai, Z., Li, C., Chen, Y., Gerotziafas, G., Zhang, Z., Whan, J., Liu, P., Elalamy, I. & Whang, C. (2020). Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. J Thromb Haemost., 120(06), 937-48.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Laura Dayane Gois Bispo; Natan Martins Machado; Caio Lopes Pinheiro de Paula; Jussiely Cunha Oliveira; Ingrid Melo Santos; Fernanda Gomes de Magalhães Soares Pinheiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
